semaglutide and cardiovascular outcomes in obesity Beyond obesity: Novo's SELECT re-defines risk management 👉 Semaglutide and Cardiovascular Outcomes

In the STEP clinical trial, patients lost an average of 15% of body weight over 68 weeks

Why Emotional Eating Doesn't Stop Overnight Emotional eating is common, affecting 44.9% of people who are overweight or obese

What Dietary and Timing Shifts Reduce Recurrent Flare-Ups

"I don't necessarily share everything I know medically on every post, but when a patient comes for the in-person visit, they get the full spiel." "I honestly think it's a little overhyped," she said of the weight-loss drugs

This information helps identify personal triggers and optimal eating patterns, and provides valuable data to share with your healthcare provider during follow-up appointments